Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization.
Biochemistry
Immune response
Microbiology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
21 Apr 2023
21 Apr 2023
Historique:
received:
28
10
2022
revised:
02
12
2022
accepted:
16
03
2023
medline:
1
4
2023
entrez:
31
3
2023
pubmed:
1
4
2023
Statut:
ppublish
Résumé
The elicitation of cross-variant neutralizing antibodies against SARS-CoV-2 represents a major goal for current COVID-19 vaccine strategies. Additionally, natural infection may also contribute to broaden neutralizing responses. To assess the contribution of vaccines and natural infection, we cross-sectionally analyzed plasma neutralization titers of six groups of individuals, organized according to the number of vaccines they received and their SARS-CoV-2 infection history. Two doses of vaccine had a limited capacity to generate cross-neutralizing antibodies against Omicron variants of concern (VOCs) in uninfected individuals, but efficiently synergized with previous natural immunization in convalescent individuals. In contrast, booster dose had a critical impact on broadening the cross-neutralizing response in uninfected individuals, to level similar to hybrid immunity, while still improving cross-neutralizing responses in convalescent individuals. Omicron breakthrough infection improved cross-neutralization of Omicron subvariants in non-previously infected vaccinated individuals. Therefore, ancestral Spike-based immunization, via infection or vaccination, contributes to broaden SARS-CoV-2 humoral immunity.
Identifiants
pubmed: 36999095
doi: 10.1016/j.isci.2023.106457
pii: S2589-0042(23)00534-5
pmc: PMC10027310
doi:
Types de publication
Journal Article
Langues
eng
Pagination
106457Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
Unrelated to the submitted work, J.B. and J.C. are founders and shareholders of AlbaJuna Therapeutics, SL. B.C. is founder and shareholder of AlbaJuna Therapeutics, SL, and AELIX Therapeutics, SL. The other authors declare no competing interests.
Références
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32826322
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
Nat Med. 2023 Jan;29(1):247-257
pubmed: 36265510
N Engl J Med. 2021 Nov 4;385(19):1761-1773
pubmed: 34525277
Am J Emerg Med. 2022 Apr;54:46-57
pubmed: 35121478
N Engl J Med. 2022 Feb 17;386(7):698-700
pubmed: 35021005
Sci Rep. 2022 Jan 28;12(1):1554
pubmed: 35091640
Viruses. 2021 Jun 12;13(6):
pubmed: 34204754
Cell Rep. 2023 Mar 6;42(4):112256
pubmed: 36952347
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
Sci Immunol. 2022 Dec 23;7(78):eade9888
pubmed: 36378074
Nat Med. 2022 Mar;28(3):477-480
pubmed: 35046572
Cell. 2022 Nov 10;185(23):4333-4346.e14
pubmed: 36257313
Vaccine. 2011 Jul 18;29(32):5250-9
pubmed: 21609746
Lancet Reg Health Eur. 2022 Oct;21:100479
pubmed: 35959415
Science. 2022 Aug 19;377(6608):890-894
pubmed: 35857529
MMWR Morb Mortal Wkly Rep. 2022 Apr 29;71(17):606-608
pubmed: 35482574
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Biochem Biophys Res Commun. 2021 Jan 29;538:187-191
pubmed: 33187644
Nature. 2022 Jul;607(7918):351-355
pubmed: 35584773
Cell. 2022 Feb 3;185(3):467-484.e15
pubmed: 35081335
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Cell. 2021 Apr 15;184(8):2183-2200.e22
pubmed: 33756110
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Age Ageing. 2022 May 1;51(5):
pubmed: 35595256
Nat Med. 2023 Mar;29(3):574-578
pubmed: 36864253
Nat Med. 2021 Dec;27(12):2127-2135
pubmed: 34650248
Immunity. 2022 Oct 11;55(10):1856-1871.e6
pubmed: 35987201
Virology. 1995 Feb 1;206(2):935-44
pubmed: 7531918
Cell Rep Med. 2022 Jan 24;3(2):100523
pubmed: 35233547
Sci Immunol. 2022 Sep 16;7(75):eabq2427
pubmed: 35653438
N Engl J Med. 2022 Mar 17;386(11):1088-1091
pubmed: 35081298
Sci Rep. 2021 Jan 28;11(1):2608
pubmed: 33510275
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
N Engl J Med. 2022 Apr 21;386(16):1579-1580
pubmed: 35294809
MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1337-1343
pubmed: 34555004
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
Nature. 2022 Mar;603(7902):700-705
pubmed: 35104835
N Engl J Med. 2022 Oct 6;387(14):1279-1291
pubmed: 36112399
N Engl J Med. 2022 Jul 7;387(1):21-34
pubmed: 35704396
Lancet Microbe. 2022 Jan;3(1):e52-e61
pubmed: 34806056
Science. 2022 Feb 11;375(6581):678-680
pubmed: 35040667
Front Microbiol. 2022 May 04;13:840757
pubmed: 35602059
Sci Immunol. 2022 Sep 23;7(75):eabq4450
pubmed: 35737747
N Engl J Med. 2022 Jul 7;387(1):86-88
pubmed: 35731894
N Engl J Med. 2022 Jan 27;386(4):340-350
pubmed: 35021002
N Engl J Med. 2022 Jun 9;386(23):2201-2212
pubmed: 35613036
Nat Commun. 2022 May 27;13(1):2979
pubmed: 35624101
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Science. 2022 Jul 15;377(6603):eabq1841
pubmed: 35699621
Nature. 2022 Mar;603(7902):693-699
pubmed: 35062016
Cell. 2021 Apr 29;184(9):2332-2347.e16
pubmed: 33761326
Nature. 2022 Jul;607(7917):128-134
pubmed: 35447027
Cell. 2022 May 26;185(11):1875-1887.e8
pubmed: 35523182